Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. Kim TW, et al. Among authors: garralda e. JAMA Oncol. 2023 Nov 1;9(11):1574-1582. doi: 10.1001/jamaoncol.2023.3867. JAMA Oncol. 2023. PMID: 37768658 Free PMC article.
Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI.
Macarro C, Bernatowicz K, Garcia-Ruiz A, Serna G, Monreal-Agüero C, Simonetti S, Figini M, Corral JF, Garay V, Vidorreta M, García-Polo García P, Merino X, Mast R, Roson N, Vieito M, Escobar M, Alexander DC, Toledo R, Nuciforo P, Garralda E, Perez-Lopez R, Grussu F. Macarro C, et al. Among authors: garralda e. J Magn Reson Imaging. 2024 Jun 19. doi: 10.1002/jmri.29484. Online ahead of print. J Magn Reson Imaging. 2024. PMID: 38895928 No abstract available.
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A. Leary A, et al. Among authors: garralda e. BMC Cancer. 2024 Jul 29;24(1):911. doi: 10.1186/s12885-024-12700-0. BMC Cancer. 2024. PMID: 39075404 Free PMC article. No abstract available.
Bispecific antibodies: advancing precision oncology.
Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, Au L. Herrera M, et al. Among authors: garralda e. Trends Cancer. 2024 Oct;10(10):893-919. doi: 10.1016/j.trecan.2024.07.002. Epub 2024 Aug 30. Trends Cancer. 2024. PMID: 39214782 Free article. Review.
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.
Martin-Liberal J, Garralda E, García-Donas J, Soto-Castillo JJ, Mussetti A, Codony C, Martin-Lluesma S, Muñoz S, Galvao V, Lostes J, Rotxes M, Prat-Vidal C, Palomero J, Muñoz A, Moreno R, García Del Muro X, Sureda A, Alemany R, Gros A, Piulats JM. Martin-Liberal J, et al. Among authors: garralda e. Future Oncol. 2024;20(32):2437-2445. doi: 10.1080/14796694.2024.2385287. Epub 2024 Aug 12. Future Oncol. 2024. PMID: 39129675 Clinical Trial.
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, Halabi S, Michiels S, Yap C, André F, Bibeau F, Curigliano G, Garralda E, Kummar S, Kurzrock R, Limaye S, Loges S, Marabelle A, Marchió C, Mateo J, Rodon J, Spanic T, Pentheroudakis G, Subbiah V. Westphalen CB, et al. Among authors: garralda e. Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25. Ann Oncol. 2024. PMID: 39187421 Free article.
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N, Castillo C, Mosteiro M, Pérez X, Aguilar S, Ruíz-Pace F, Gil M, Cuadra C, Ruffinelli JC, Martínez M, Losa F, Soler G, Teulé À, Castany R, Gallego R, Ruíz A, Garralda E, Élez E, Vivancos A, Tabernero J, Salazar R, Dienstmann R, Santos Vivas C. Mulet Margalef N, et al. Among authors: garralda e. Mol Oncol. 2023 Sep;17(9):1908-1916. doi: 10.1002/1878-0261.13444. Epub 2023 Jun 12. Mol Oncol. 2023. PMID: 37097008 Free PMC article.
Agnostic drug development revisited.
Hernando-Calvo A, Rossi A, Vieito M, Voest E, Garralda E. Hernando-Calvo A, et al. Among authors: garralda e. Cancer Treat Rev. 2024 Jul;128:102747. doi: 10.1016/j.ctrv.2024.102747. Epub 2024 Apr 27. Cancer Treat Rev. 2024. PMID: 38763053 Review.
170 results